




A Gated on CD20+ LPS+ IgD+ CD27- (LPS+ Naïve) [TD volunteers]




B




C



D



E



F

Markers evaluated

	pAkt	pp38MAPK	pBtk	pNFkB	pErk1/2	pSyk
Sm CD27+	AroundTD (Net%; P*=0.61)	AroundTD (Net%; P=0.088)	AroundTD (Net%; P=0.024) Fig 7 B	AroundTD (Net%; P=0.011) Fig 7 E	AroundTD (Net%; P=0.12)	AroundTD (Net%; P=0.13)
Sm CD27-	AroundTD (Net%; P=0.93)	AroundTD (Net%; P=0.26)	AroundTD (Net%; P=0.21)	AroundTD (Net%; P=0.77)	AroundTD (Net%; P=0.037) Fig 7 H	AroundTD (Net%; P=0.11)
Um	AfterTD (Net%; P=0.50)	AroundTD (Net%; P=0.52)	AroundTD (Net%; P=0.35)	AroundTD (Net%; P=0.77)	AroundTD (Net%; P=0.17)	AroundTD (Net%; P=0.29)
Naïve	AroundTD (Net%; P=0.021) Fig 7 K	AroundTD (Net%; P=0.20)	AroundTD (Net%; P=0.48)	AroundTD (Net%; P=0.93)	AroundTD (Net%; P=0.31)	AroundTD (Net%; P=0.24)

* P-values for differences between TD and NoTD [Mixed effects model]

B_M Populations